Advocates call on TB Alliance to make public the pretomanid licensing agreement with Mylan
Advocates request full access to the terms of the agreement granting Mylan the rights to commercialize pretomanid.
On 10 June 2019, TB advocates sent an open letter to TB Alliance requesting that the organization make public its recent agreement with Mylan, announced 18 April 2019.
“Full access to the terms of the agreement granting Mylan the rights to commercialize pretomanid is critical to our work to ensure equitable access to TB treatments.”
The signatories requested a response by 18 June 2019.
To read the full letter, click here.
